Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Christine Fisher

Concepts (246)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Uterine Cervical Neoplasms
14
2024
232
4.520
 Why?
Brachytherapy
13
2023
104
4.260
 Why?
Endometrial Neoplasms
9
2025
164
2.080
 Why?
Radiotherapy Planning, Computer-Assisted
7
2024
123
1.790
 Why?
Breast Neoplasms
20
2024
2131
1.750
 Why?
Hysterectomy
5
2019
118
1.740
 Why?
Uterine Neoplasms
5
2023
102
1.570
 Why?
Carcinosarcoma
3
2023
17
1.390
 Why?
Genital Neoplasms, Female
4
2024
81
1.050
 Why?
Databases, Factual
5
2021
1264
1.030
 Why?
Radiation Oncology
5
2022
75
1.020
 Why?
Neoplasm Staging
17
2021
1288
0.930
 Why?
Radiotherapy, Intensity-Modulated
2
2024
128
0.890
 Why?
Radiosurgery
4
2023
318
0.870
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2017
54
0.800
 Why?
Chemoradiotherapy
4
2019
209
0.780
 Why?
Healthcare Disparities
2
2018
579
0.720
 Why?
Radiotherapy, Adjuvant
6
2019
209
0.700
 Why?
Simulation Training
1
2021
82
0.680
 Why?
Margins of Excision
1
2019
37
0.620
 Why?
Female
55
2025
68016
0.610
 Why?
Insurance, Health
2
2018
267
0.610
 Why?
Aquaporin 4
1
2019
95
0.600
 Why?
Necrosis
1
2019
228
0.590
 Why?
Antineoplastic Agents, Immunological
1
2019
175
0.540
 Why?
Perioperative Care
1
2018
149
0.530
 Why?
Carcinoma, Neuroendocrine
1
2016
32
0.520
 Why?
Insurance Coverage
1
2018
219
0.520
 Why?
Antineoplastic Combined Chemotherapy Protocols
6
2023
1558
0.520
 Why?
Aged
25
2024
21892
0.510
 Why?
Standard of Care
1
2016
72
0.510
 Why?
Middle Aged
29
2024
30812
0.490
 Why?
SEER Program
6
2021
206
0.490
 Why?
Adenocarcinoma
4
2024
888
0.470
 Why?
Neoplasms
3
2022
2460
0.460
 Why?
Humans
60
2025
128019
0.460
 Why?
Survival Rate
7
2019
1870
0.460
 Why?
Health Plan Implementation
1
2015
137
0.450
 Why?
Neoplasm Recurrence, Local
10
2021
955
0.450
 Why?
Medical Errors
1
2015
104
0.450
 Why?
Carcinoma, Ductal, Breast
1
2014
82
0.440
 Why?
Radiotherapy Dosage
5
2023
250
0.440
 Why?
Quality Assurance, Health Care
1
2015
315
0.420
 Why?
Tumor Suppressor Protein p53
3
2023
504
0.420
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1343
0.410
 Why?
Carcinoma
1
2014
215
0.400
 Why?
Pelvis
1
2013
101
0.400
 Why?
Combined Modality Therapy
6
2020
1199
0.390
 Why?
Practice Patterns, Physicians'
2
2018
1260
0.380
 Why?
Internship and Residency
1
2021
1043
0.380
 Why?
Prostatectomy
1
2012
106
0.380
 Why?
Receptor, ErbB-2
5
2021
325
0.380
 Why?
Vulvar Neoplasms
2
2024
11
0.360
 Why?
Carcinoma, Endometrioid
2
2023
47
0.350
 Why?
Mastectomy, Segmental
4
2020
85
0.340
 Why?
Adult
21
2024
35176
0.330
 Why?
Mutation
3
2023
3682
0.330
 Why?
United States
13
2022
13785
0.330
 Why?
Lymphatic Metastasis
3
2021
317
0.310
 Why?
Re-Irradiation
2
2020
8
0.310
 Why?
Aged, 80 and over
12
2024
7029
0.300
 Why?
Cancer Pain
2
2018
26
0.280
 Why?
Analgesics, Opioid
3
2021
886
0.270
 Why?
Treatment Outcome
9
2023
10110
0.270
 Why?
Prostatic Neoplasms
2
2012
1011
0.270
 Why?
Sarcoma
2
2021
176
0.260
 Why?
Retrospective Studies
14
2024
14404
0.260
 Why?
Mastectomy
3
2020
131
0.250
 Why?
Chemotherapy, Adjuvant
4
2021
377
0.240
 Why?
Neoadjuvant Therapy
2
2018
381
0.240
 Why?
Consensus
2
2024
607
0.230
 Why?
Regression Analysis
2
2019
978
0.230
 Why?
Papillomavirus Infections
2
2019
290
0.220
 Why?
Young Adult
8
2021
12281
0.220
 Why?
Follow-Up Studies
4
2018
4853
0.220
 Why?
Prognosis
6
2023
3766
0.220
 Why?
Medical Oncology
4
2019
271
0.220
 Why?
Carcinoma, Renal Cell
2
2015
179
0.210
 Why?
Positron-Emission Tomography
1
2024
283
0.210
 Why?
Adenocarcinoma, Clear Cell
1
2023
14
0.210
 Why?
Kaplan-Meier Estimate
4
2021
851
0.200
 Why?
Tertiary Care Centers
1
2023
146
0.200
 Why?
Hodgkin Disease
2
2016
134
0.200
 Why?
Brain Neoplasms
2
2023
1163
0.200
 Why?
Hydrocephalus
1
2023
108
0.190
 Why?
Colonic Neoplasms
1
2024
242
0.190
 Why?
beta Catenin
2
2023
217
0.180
 Why?
Kidney Neoplasms
2
2015
349
0.180
 Why?
Veterans
2
2022
1397
0.180
 Why?
Carcinoma, Squamous Cell
2
2017
620
0.170
 Why?
Cancer Care Facilities
1
2020
32
0.170
 Why?
Magnetic Resonance Imaging
2
2024
3371
0.170
 Why?
High-Throughput Nucleotide Sequencing
1
2023
484
0.170
 Why?
Benzodiazepines
1
2021
130
0.170
 Why?
Immunohistochemistry
1
2023
1663
0.160
 Why?
Lymph Nodes
1
2021
465
0.160
 Why?
Triple Negative Breast Neoplasms
1
2021
191
0.150
 Why?
Referral and Consultation
1
2024
724
0.150
 Why?
Practice Guidelines as Topic
2
2017
1482
0.150
 Why?
Pain Management
2
2018
317
0.150
 Why?
Patient Acceptance of Health Care
1
2024
756
0.140
 Why?
Relative Biological Effectiveness
1
2017
3
0.140
 Why?
Proportional Hazards Models
2
2018
1194
0.140
 Why?
Adolescent
5
2019
20158
0.140
 Why?
Radiotherapy, Conformal
1
2017
70
0.130
 Why?
Machine Learning
1
2021
442
0.130
 Why?
Tomography, X-Ray Computed
2
2024
2509
0.130
 Why?
Pancreatic Neoplasms
1
2024
873
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
71
0.130
 Why?
Propensity Score
1
2018
264
0.130
 Why?
Antineoplastic Agents
3
2017
2041
0.130
 Why?
Breast
1
2017
152
0.130
 Why?
Logistic Models
2
2018
1975
0.130
 Why?
Radiotherapy Setup Errors
1
2015
3
0.130
 Why?
Radiation Injuries
1
2017
135
0.130
 Why?
Neoplasm Grading
4
2019
283
0.120
 Why?
Neoplasms, Second Primary
1
2016
106
0.120
 Why?
Quality Control
1
2015
156
0.120
 Why?
Curriculum
1
2021
909
0.120
 Why?
Medically Uninsured
1
2015
127
0.120
 Why?
Risk Reduction Behavior
1
2016
208
0.120
 Why?
Physicians
1
2023
858
0.120
 Why?
Risk Factors
6
2020
9696
0.120
 Why?
Radiation Tolerance
1
2015
97
0.120
 Why?
Checklist
1
2015
93
0.110
 Why?
Drug Administration Schedule
1
2016
755
0.110
 Why?
Clinical Competence
1
2021
1007
0.110
 Why?
Soft Tissue Neoplasms
1
2015
112
0.110
 Why?
Cancer Vaccines
2
2005
163
0.110
 Why?
Case-Control Studies
2
2019
3324
0.110
 Why?
Internet
1
2018
613
0.110
 Why?
Breast Neoplasms, Male
1
2013
29
0.110
 Why?
Tumor Burden
1
2014
283
0.110
 Why?
Skin Neoplasms
2
2024
818
0.110
 Why?
Randomized Controlled Trials as Topic
1
2019
1356
0.100
 Why?
Gene Expression Profiling
2
2017
1681
0.100
 Why?
Guideline Adherence
1
2017
523
0.100
 Why?
Socioeconomic Factors
1
2017
1211
0.100
 Why?
Neoplasm Invasiveness
1
2014
477
0.100
 Why?
Bone Neoplasms
1
2015
229
0.100
 Why?
Biomarkers, Tumor
4
2023
1175
0.100
 Why?
Patient Safety
1
2015
286
0.100
 Why?
Texas
1
2012
227
0.090
 Why?
Poly-ADP-Ribose Binding Proteins
2
2023
33
0.090
 Why?
Male
12
2024
62757
0.090
 Why?
DNA Polymerase II
2
2023
38
0.090
 Why?
Medicaid
1
2015
433
0.090
 Why?
Peptide Fragments
2
2005
688
0.090
 Why?
Registries
1
2018
1873
0.090
 Why?
Disease Management
1
2014
583
0.090
 Why?
Liver Neoplasms
1
2015
633
0.090
 Why?
Lung Neoplasms
1
2023
2327
0.080
 Why?
Age Factors
1
2017
3100
0.080
 Why?
Cohort Studies
3
2021
5378
0.080
 Why?
Quality Indicators, Health Care
2
2022
296
0.080
 Why?
Survival Analysis
1
2012
1262
0.080
 Why?
Melanoma
1
2015
722
0.080
 Why?
Risk Assessment
2
2020
3223
0.070
 Why?
Opioid-Related Disorders
3
2021
480
0.070
 Why?
Epidemics
2
2018
82
0.070
 Why?
Fertility Preservation
2
2019
53
0.070
 Why?
Prospective Studies
4
2023
7035
0.060
 Why?
Medicare
2
2021
715
0.060
 Why?
Prevalence
1
2012
2541
0.060
 Why?
Gynecology
2
2018
175
0.060
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2005
146
0.060
 Why?
Prostate-Specific Antigen
1
2005
162
0.060
 Why?
Paget Disease, Extramammary
1
2024
4
0.060
 Why?
Radiotherapy
2
2015
185
0.050
 Why?
DNA Mismatch Repair
1
2023
47
0.050
 Why?
Information Seeking Behavior
1
2023
33
0.050
 Why?
Aromatase
1
2023
31
0.050
 Why?
Needles
1
2023
56
0.050
 Why?
Time Factors
4
2020
6479
0.050
 Why?
Receptors, Estrogen
2
2016
424
0.050
 Why?
Anthracyclines
1
2021
46
0.050
 Why?
Taxoids
1
2021
95
0.050
 Why?
Precision Medicine
1
2025
384
0.050
 Why?
Trastuzumab
1
2021
100
0.040
 Why?
Clinical Trials, Phase I as Topic
1
2020
50
0.040
 Why?
Hospitals, University
1
2021
176
0.040
 Why?
Estrogens
1
2023
342
0.040
 Why?
Quinolines
1
2021
154
0.040
 Why?
Radiometry
1
2019
47
0.040
 Why?
Microsatellite Instability
1
2019
37
0.040
 Why?
Chemoradiotherapy, Adjuvant
1
2019
41
0.040
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
81
0.040
 Why?
Organ Sparing Treatments
1
2019
32
0.040
 Why?
Cervix Uteri
1
2019
50
0.040
 Why?
Papanicolaou Test
1
2019
42
0.040
 Why?
Radiotherapy, Image-Guided
1
2018
33
0.040
 Why?
Guidelines as Topic
1
2020
260
0.040
 Why?
Papillomaviridae
1
2019
113
0.040
 Why?
India
1
2018
170
0.040
 Why?
Neoplasm Metastasis
1
2020
608
0.040
 Why?
United States Department of Veterans Affairs
1
2022
633
0.040
 Why?
PTEN Phosphohydrolase
1
2019
157
0.040
 Why?
Equipment Design
1
2019
515
0.040
 Why?
Vagina
1
2019
175
0.040
 Why?
Organs at Risk
1
2017
31
0.030
 Why?
Predictive Value of Tests
1
2021
1934
0.030
 Why?
Statistics, Nonparametric
1
2017
419
0.030
 Why?
Skin Ulcer
1
2015
13
0.030
 Why?
Abdominal Neoplasms
1
2015
34
0.030
 Why?
HLA-A2 Antigen
2
2005
47
0.030
 Why?
Antibodies, Monoclonal, Humanized
1
2021
754
0.030
 Why?
Thoracic Neoplasms
1
2015
35
0.030
 Why?
Societies, Medical
1
2019
741
0.030
 Why?
Reoperation
1
2017
541
0.030
 Why?
Fibrosis
1
2017
513
0.030
 Why?
Odds Ratio
1
2017
1018
0.030
 Why?
Clinical Decision-Making
1
2017
302
0.030
 Why?
Evidence-Based Medicine
1
2018
709
0.030
 Why?
Disease Progression
2
2015
2598
0.030
 Why?
Biopsy
1
2017
1077
0.030
 Why?
Confidence Intervals
1
2013
316
0.030
 Why?
Age Distribution
1
2013
369
0.030
 Why?
Sex Distribution
1
2013
356
0.030
 Why?
Membrane Proteins
1
2019
1105
0.030
 Why?
Clinical Trials as Topic
1
2017
997
0.020
 Why?
Skin
1
2017
711
0.020
 Why?
Comorbidity
1
2017
1537
0.020
 Why?
Vinblastine
1
2011
68
0.020
 Why?
Receptors, Progesterone
1
2013
341
0.020
 Why?
Dacarbazine
1
2011
94
0.020
 Why?
Surveys and Questionnaires
1
2023
5353
0.020
 Why?
Mass Screening
1
2019
1145
0.020
 Why?
Remission Induction
1
2011
267
0.020
 Why?
Analysis of Variance
1
2013
1266
0.020
 Why?
Colorado
1
2020
4369
0.020
 Why?
Bleomycin
1
2011
240
0.020
 Why?
Doxorubicin
1
2011
322
0.020
 Why?
Algorithms
1
2017
1609
0.020
 Why?
Sex Factors
1
2013
1942
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2261
0.020
 Why?
Incidence
1
2013
2614
0.020
 Why?
Cytotoxicity Tests, Immunologic
1
2005
41
0.020
 Why?
Cytotoxicity, Immunologic
1
2005
216
0.010
 Why?
T-Lymphocytes, Cytotoxic
1
2005
168
0.010
 Why?
Cross-Sectional Studies
1
2015
5034
0.010
 Why?
Immunoconjugates
1
2005
101
0.010
 Why?
Leukocytes, Mononuclear
1
2005
539
0.010
 Why?
Interferon-gamma
1
2005
760
0.010
 Why?
CD8-Positive T-Lymphocytes
1
2005
840
0.010
 Why?
Cell Line, Tumor
1
2005
3168
0.010
 Why?
Child
1
2013
20636
0.010
 Why?
Fisher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (246) concept(s)
_
Co-Authors Expand Description
See all (46) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)